拉米夫定治疗乙型肝炎肝衰竭对患者HBVDNA干预作用.docVIP

拉米夫定治疗乙型肝炎肝衰竭对患者HBVDNA干预作用.doc

  1. 1、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
  2. 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  3. 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  4. 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  5. 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  6. 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  7. 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
拉米夫定治疗乙型肝炎肝衰竭对患者HBVDNA干预作用

拉米夫定治疗乙型肝炎肝衰竭对患者HBVDNA干预作用   [摘要] 目的 探讨拉米夫定治疗乙型肝炎肝衰竭对患者HBV-DNA的干预作用。方法 研究对象整群选取于该院2012年12月―2014年12月收治的74例慢加急性乙型肝炎肝衰竭患者,按随机数字表法分为对照组与观察组,各37例。对照组患者接受常规基础治疗;观察组患者同时给予拉米夫定治疗。统计两组患者治疗前后血清总胆红素(TBiL)水平、凝血酶原活动度(PTA)及乙肝病毒基因(HBVDNA)载量。 结果 治疗后,较对照组,观察组TBiL(93.52±56.31)μmol/L和HBV-DNA(4.15±1.54)lg IU/mL低,PAT(63.54±3.69)高,两组比较差异均有统计学意义(P0.05)。结论 拉米夫定治疗乙型肝炎肝衰竭患者疗效确切,能有效降低血清HBV-DNA水平,抑制病毒复制。   [关键词] 拉米夫定;乙型肝炎;肝衰竭;HBV-DNA   [中图分类号] R5 [文献标识码] A [文章编号] 1674-0742(2016)01(b)-0133-02   Intervention Effect of Lamivudine in Treatment of Hepatitis B Liver Failure on HBVDNA in Patients   LIU Zhi-hui   Department of gastroenterology, Jiaozuo Second Peoples Hospital(The First Affiliated Hospital of Henan Polytechnic University),Jiaozuo, Henan Province, 454000 China   [Abstract] Objective To observe the intervention effect of lamivudine in treatment of hepatitis B liver failure on HBVDNA in patients. Methods 74 cases of patients with acute-on-chronic hepatitis B liver failure treated in our hospital from December 2012 to December 2014 were selected as the research object and randomly divided into two groups with 37 cases in each, the control group were given conventional basis treatment, the observation group were given lamivudine treatment at the same time, the serum total bilirubin level (TBiL), prothrombin Activity (PTA) and hepatitis B virus gene capacity of the two groups before and after treatment were given statistics. Results After treatment, the TBiL ,μmol/L and HBV-DNA were(93.52±56.31),(4.15±1.54)and lg IU /ml in the observation group, which were lower than those in the control group; the PAT was (63.54±3.69)in the observation group, which was higher than that in the control group, and the differences were statistically significant between groups by comparison (P0.05). Conclusion Lamivudine in treatment of hepatitis B liver failure has a definite curative effect and can effectively reduce the serum HBV-DNA level and inhibit viral replication.   [Key words] Lamivudine; Hepa

您可能关注的文档

文档评论(0)

317960162 + 关注
实名认证
文档贡献者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档